ArticleInternational journal of general medicine2025
Investigation of the Impact Factors and Efficacy of N-Butylphthalide (NBP) on Functional Outcomes Following Mechanical Thrombectomy in Stroke Patients.
Article in International journal of general medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Engineered Brain-Targeted Exosomes Delivering FGF1 for Sustained Glycemic Regulation and Multitarget Neurovascular Protection in Diabetic Stroke.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Ischemic stroke was a major cause of mortality and disability worldwide. Mechanical thrombectomy (MT) has improved acute ischemic stroke treatment by restoring blood flow in large vessel occlusions. Yet, reperfusion injury remains a challenge, necessitating adjunctive neuroprotective strategies to enhance recovery. N-butylphthalide (NBP), with its anti-inflammatory and antioxidative properties, may improve functional outcomes post-MT. Methods: This retrospective study analyzed 120 ischemic stroke patients treated with MT at a single institution from December 2020 to December 2022. Patients were divided into a routine care group (n = 56) and an NBP treatment group (n = 64). Baseline characteristics, comorbidities, and biochemical profiles were assessed. Functional outcomes were measured by the modified Rankin Scale (mRS) at 90 days. Statistical analysis included correlation and logistic regression to identify factors influencing recovery. Results: Among the NBP group, a significantly higher percentage achieved favorable mRS scores (0-2) compared to the routine care group (62.50% vs 37.50%, P = 0.006). Smoking (OR 0.320, P = 0.021), diabetes (OR 0.246, P = 0.022), and elevated hs-CRP levels (OR 0.407, P = 0.004) were identified as negative predictors of functional recovery. Conversely, NBP treatment significantly improved outcomes (OR 3.248, P = 0.008). Conclusion: The study supports the potential of NBP as an effective adjunctive therapy in improving recovery following MT in ischemic stroke patients. Modifiable factors such as smoking and diabetes, along with elevated hs-CRP, negatively influence outcomes, highlighting the importance of comprehensive management.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.